Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Sekeres MA, et al. Among authors: gore sd. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9. J Clin Oncol. 2017. PMID: 28486043 Free PMC article. Clinical Trial.
Myelodysplastic syndrome.
Mufti G, List AF, Gore SD, Ho AY. Mufti G, et al. Among authors: gore sd. Hematology Am Soc Hematol Educ Program. 2003:176-99. doi: 10.1182/asheducation-2003.1.176. Hematology Am Soc Hematol Educ Program. 2003. PMID: 14633782 Review.
Intravenous azacitidine for MDS.
Gore SD. Gore SD. Clin Adv Hematol Oncol. 2007 Mar;5(3):234. Clin Adv Hematol Oncol. 2007. PMID: 17519884 No abstract available.
Myelodysplastic syndromes.
Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P; NCCN Myelodysplastic Syndromes Panel. Greenberg PL, et al. Among authors: gore sd. J Natl Compr Canc Netw. 2008 Oct;6(9):902-26. J Natl Compr Canc Netw. 2008. PMID: 18926100 No abstract available.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Fenaux P, et al. Among authors: gore sd. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. Lancet Oncol. 2009. PMID: 19230772 Free PMC article. Clinical Trial.
A phase 2 study of vorinostat in acute myeloid leukemia.
Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD; Mayo P2C Phase II Consortium. Schaefer EW, et al. Among authors: gore sd. Haematologica. 2009 Oct;94(10):1375-82. doi: 10.3324/haematol.2009.009217. Haematologica. 2009. PMID: 19794082 Free PMC article. Clinical Trial.
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS; Eastern Cooperative Oncology Group Leukemia Committee. Litzow MR, et al. Among authors: gore sd. Br J Haematol. 2010 Jan;148(2):217-25. doi: 10.1111/j.1365-2141.2009.07917.x. Epub 2009 Oct 5. Br J Haematol. 2010. PMID: 19804455 Free PMC article. Clinical Trial.
277 results